Takeda’s oveporexton tablets received formal approval from the National Medical Products Administration (NMPA) of China on 21 July 2026. This makes China the first country to approve the drug globally — described in the source as a milestone “China first report, China first launch”for a novel-mechanism therapy that was developed and filed in parallel with other major markets. Oveporexton is a selective orexin-2 receptor (OX2R) agonist, approved for the treatment of narcolepsy type 1 (NT1) in adolescents (16 years and older) and adults.
An Unmet Need Decades in the Making
NT1 is a chronic, rare neurological disease. Its core pathology is the loss of orexin-producing neurons, leading to markedly reduced or absent orexin (also known as hypocretin) levels in the brain. Because orexin is a key regulator of the sleep–wake cycle, patients repeatedly experience uncontrollable daytime sleep attacks.
Two additional hallmark features are cataplexy and sleep paralysis. Cataplexy is the sudden loss of muscle tone triggered by strong emotions (laughter, anger, surprise); mild episodes cause only knee buckling or head drooping, while severe ones can drop a patient to the floor. Sleep paralysis typically occurs at sleep onset or just after awakening — the patient is fully conscious but unable to move the body, often with vivid, frightening hallucinations. Disordered orexin signaling also commonly impairs cognition, with reduced attention, weakened executive function, and impaired memory.
For decades, NT1 care has remained largely symptomatic. Most patients need multiple agents: central nervous system stimulants such as modafinil or methylphenidate to address daytime sleepiness; antidepressants or sodium oxybate to control cataplexy and improve nighttime sleep.
These regimens leave meaningful gaps. None targets the underlying orexin deficiency, so they cannot restore normal sleep–wake physiology. Several commonly used agents also carry troublesome adverse effects — stimulants may cause palpitations and anxiety, with tolerance developing over time, while sodium oxybate has potential for misuse and a complex dosing schedule. This long-standing treatment plateau is what gives oveporexton’s mechanism its significance: it is the first to point therapy directly at the root cause.
Mechanism and Clinical Data
NT1’s core pathology is orexin neuron loss causing endogenous orexin deficiency, which in turn drives wakefulness dysfunction. Oveporexton selectively activates OX2R, replacing the downstream neurotransmitter activity lost to orexin deficiency and intervening in NT1 pathology at its source. Where conventional approaches are largely symptomatic — using external stimulation to force wakefulness — oveporexton is mechanism-targeted, rebuilding wakefulness by reactivating the orexin signaling pathway. By activating OX2R, the drug promotes wakefulness, reduces cataplexy and other abnormal REM-related phenomena, and improves the broad range of daytime and nighttime symptoms.
Approval is based on two pivotal global Phase 3 studies, FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002), covering 19 countries/regions and designed to evaluate efficacy, safety, and tolerability of oveporexton versus placebo over 12 weeks in patients with NT1. The primary endpoint was improvement in excessive daytime sleepiness as measured by the Maintenance of Wakefulness Test (MWT). Both Phase 3 studies met all primary and secondary endpoints. At week 12, every active dose group showed statistically significant improvements versus placebo across all primary and secondary endpoints.
Daytime sleepiness: at week 12, the MWT mean sleep latency and Epworth Sleepiness Scale (ESS) scores in each active dose group showed statistically significant improvements versus baseline. Most subjects receiving the 2/2 mg dose achieved wakefulness in the MWT within the normal range (≥20 minutes), and approximately 85% of subjects had ESS scores equivalent to healthy individuals (≤10).
Cataplexy: median cataplexy-free days rose from 0 days per week at baseline to 4-5 days per week at week 12 versus placebo. Additional exploratory data presented at SLEEP 2026 (the 2026 annual meeting of the American Academy of Sleep Medicine and the Associated Professional Sleep Societies) further demonstrated broad benefit: on all six dimensions of the Functional Impact of Narcolepsy Instrument (FINI) — fatigue, cognitive function, cataplexy, social activities, daily activities, and daily responsibilities — oveporexton showed statistically significant improvement versus placebo (p<0.001), with most patients’ scores reaching normal reference thresholds and approaching those of healthy individuals.
In cognitive function — a long-standing concern — objective neuropsychological testing and patient self-report both favored oveporexton over placebo on attention, executive function, and memory. On the FINI cognitive dimension, approximately 70% of treated patients did not report significant cognitive difficulty, versus only approximately 15% on placebo.
Safety: oveporexton was generally well tolerated, consistent with prior studies. No treatment-related serious adverse events were reported. The most common adverse events were insomnia, urinary urgency, and urinary frequency.
Global OX2R Competitive Landscape
Drugs targeting OX2R divide into two mechanistic tracks: OX2R agonists, primarily for hypersomnia disorders such as NT1, and OX2R antagonists, used for insomnia by blocking overactive wakefulness signals to induce physiologic sleep. According to the source, approximately 21 oral selective OX2R-related drugs are in active global development; 6 have been approved and 3 are in Phase 3.
Until oveporexton’s approval, every marketed product in this space was an orexin receptor antagonist. China saw a wave of dual orexin receptor antagonist (DORA) approvals in 2025-2026: lemborexant in May 2025, the first DORA approved in China; daridorexant in June 2025, co-developed by Idorsia and Simcere ; and fazansertil in May 2026, the first domestically developed DORA in China. DORAs block both OX1R and OX2R. Because OX1R is more involved in stress response and emotional regulation, non-selective inhibition raises the risk of off-target effects such as sleep paralysis.
Two Chinese players are pursuing selective OX2R antagonists in an effort to reduce those off-target risks. Hansoh Pharma’s HS-10506 has begun Phase 3 with a planned enrollment of approximately 732 subjects, targeting sleep disorders. Kanghong Pharma’s KHN707 is in Phase 1.
Globally, the OX2R agonist pipeline is larger than the antagonist pipeline, with 12 candidates, 6 of them in Phase 1. Takeda’s oveporexton leads the field and has now been approved in China; in February 2026, its new drug application was accepted by the U.S. Food and Drug Administration (FDA) with Priority Review, with a Prescription Drug User Fee Act (PDUFA) target date of 10 August 2026. The next closest competitor is Alkermes’ alixorexton (ALKS 2680). In the Vibrance-1 Phase 2 study in NT1, all dose groups reached normal wakefulness levels (mean sleep latency >20 minutes), which led the FDA to grant Breakthrough Therapy designation; a global Phase 3 program has been launched. In March 2026, Eli Lilly announced the acquisition of Centessa Pharmaceuticals for an upfront payment of USD 6.3 billion and a maximum total consideration of USD 7.8 billion, securing Centessa’s lead OX2R agonist cleminorexton (ORX750). In the Phase 2a CRYSTAL-1 trial, NT1 patients receiving 1.5 mg showed MWT improvement exceeding 20 minutes and a relative reduction of 87% in weekly cataplexy rate. Beyond cleminorexton, Centessa’s pipeline includes ORX142 (Phase 1, targeting neurodegenerative diseases) and ORX489 (preclinical, in neuropsychiatric indications), forming a portfolio that extends from sleep disorders into broader neuroscience.
Global Innovation Drugs Now Arriving First in China
For a long time, first launches of global innovative drugs were concentrated in the United States (FDA) and Europe (European Medicines Agency, EMA). As the world’s second-largest pharmaceutical market, China has historically sat in the second tier of the global launch sequence, with new drugs typically reaching Chinese patients years after their Western approvals. China-first launches of innovative drugs were once difficult to achieve.
Starting in 2015, China launched regulatory reform centered on “raising review quality, clearing the registration application backlog, and encouraging innovation.” Priority review, breakthrough therapy designation, conditional approval, and the implied clinical trial license all came into effect, narrowing the time lag for new drug approvals in China. The “global synchronized development and synchronized filing” strategy that the NMPA has actively promoted in recent years is aimed directly at the historical pain point of delayed drug access for Chinese patients. Where multinational companies once commonly filed in Europe and the United States first and submitted to China later, leaving Chinese patients waiting years for access, synchronized development and filing means that clinical studies in China can run in parallel with global multicenter trials and that registration dossiers can be submitted simultaneously with major regulators worldwide.
In September 2024, Takeda’s oveporexton was granted Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) for NT1. In 2026 the review timeline accelerated substantially: on 16 January, Takeda submitted the NDA in China — the first global filing; only four days later, on 20 January, the application was placed into priority review. It was only afterward, in February and June 2026, that Takeda submitted applications to the United States and Japan, respectively. After only six months of rigorous review, the NMPA approved oveporexton on 21 July 2026 for NT1 in patients aged 16 and older. This pace made China the first country in the world to approve this important novel drug.
Conclusion
Takeda’s oveporexton achieving a China-first launch fills a long-standing gap in disease-modifying therapy for narcolepsy type 1, and at the same time stands as a tangible illustration of the results of China’s drug regulatory reform. As the synchronized development and synchronized filing mechanism continues to deepen, more global first-in-class innovative drugs are expected to reach simultaneous or even first launch in China, allowing domestic patients faster access to cutting-edge therapies worldwide.